CohBar set to open at near 6-month high as early-stage NASH study hits main goal

CohBar

11/08/2021 12:38

** Shares of CohBar Inc  CWBR.O  up 51.2% at $1.95 in
premarket trade; stock on track to open at a near six-month high
    ** The clinical-stage biotechnology co said on Tuesday its
drug under development for treating Nonalcoholic Steatohepatitis
(NASH) and obesity met the main goal in early-stage study as it
was well-tolerated with no serious adverse effects 
    ** Co says it observed a trend towards lower body weight
after four weeks of treatment in study when comparing CB4211 to
placebo  urn:newsml:reuters.com:*:nGNX8Z7XT1  
    ** Co says comparing CB4211 to placebo also showed
significant reductions in key biomarkers of liver damage, ALT
and AST, and a significant decrease in glucose levels
    ** Separately, CWBR announced Q2 results and posted a loss
of 8 cents per share  urn:newsml:reuters.com:*:nGNXQj2sm
    ** As of Tuesday's close, stock down 3.73% YTD

 (Reporting by Rishi Kant in Bengaluru)
 ((Rishi.Kant@thomsonreuters.com; +91-8874445238; Twitter:
@RishiKant98))